Video Experimental Relacionado
Updated: Jul 22, 2026
14:26
A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
Efecto de la DHEA en la grasa abdominal y la acción de la insulina en mujeres y hombres de edad avanzada: un ensayo
Dennis T Villareal1, John O Holloszy
1Division of Geriatrics and Nutritional Science, Department of Medicine, Washington University School of Medicine, St Louis, Mo 63110, USA.
JAMA
|November 13, 2004
Resumen
La terapia con deshidroepiandrosterona (DHEA) redujo significativamente la grasa abdominal y mejoró la sensibilidad a la insulina en personas mayores. Esto sugiere que la DHEA puede ayudar a prevenir y tratar el síndrome metabólico relacionado con la obesidad.
Área de la Ciencia:
- Endocrinología Endocrinología.
- Salud Metabólica La salud metabólica es la salud metabólica.
- Gerontología Gerontología.
Sus antecedentes:
- La deshidroepiandrosterona (DHEA) muestra potencial en modelos animales para reducir la grasa abdominal y mejorar la resistencia a la insulina.
- Sus efectos sobre la obesidad abdominal humana y la acción de la insulina permanecen en gran parte sin investigar.
- La DHEA es accesible como un suplemento dietético de venta libre.
Objetivo del estudio:
- Para investigar la eficacia de la terapia de reemplazo de DHEA en la disminución de la grasa abdominal.
- Evaluar el impacto de la DHEA en la acción de la insulina en personas de edad avanzada.
Principales métodos:
- Se realizó un ensayo aleatorizado, doble ciego, controlado con placebo durante 6 meses.
- Cincuenta y seis participantes de edad avanzada con disminución de DHEA relacionada con la edad recibieron 50 mg/d de DHEA o un placebo.
- La grasa abdominal (visceral y subcutánea) y las respuestas de glucosa / insulina a través de la prueba de tolerancia oral a la glucosa (OGTT) fueron las medidas de resultado primarias.
Principales resultados:
- La terapia con DHEA condujo a reducciones significativas en la grasa abdominal visceral y subcutánea en comparación con el placebo.
- El área de insulina debajo de la curva (AUC) durante OGTT disminuyó significativamente con el tratamiento con DHEA.
- A pesar de los niveles más bajos de insulina, el AUC de la glucosa se mantuvo sin cambios, lo que indica una mejor sensibilidad a la insulina.
Conclusiones:
- La terapia de reemplazo de DHEA demostró una reducción significativa de la adiposidad abdominal.
- La terapia mejoró la acción de la insulina, lo que sugiere un papel potencial en el manejo del síndrome metabólico.
- La DHEA puede ser una opción viable para prevenir y tratar el síndrome metabólico asociado con la obesidad abdominal.
Más Videos Relacionados
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
06:13Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
Videos de Conceptos Relacionados
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...